Vyvgart Hytrulo Market Report 2026

Vyvgart Hytrulo Market Overview

• The Vyvgart Hytrulo market growth in the historic period has been driven by increasing diagnosis of generalized myasthenia gravis, expansion of biologic autoimmune treatments • Market expansion is supported by increasing adoption of subcutaneous biologics, expansion into additional autoimmune indications • Growth Driver: Impact Of Rising Autoimmune Disorders On The Growth Of The Market • Market Trend: Advancement In Targeted Therapy Offers Flexible And Effective Treatment For gMG Patients • North America was the largest region in 2025.

What Is Covered Under Vyvgart Hytrulo Market?

VYVGART hytrulo is a subcutaneous formulation of vyvgart (efgartigimod alfa-fcab), designed for the treatment of generalized myasthenia gravis (gMG) in adults who are positive for anti-acetylcholine receptor (AChR) antibodies. Unlike the intravenous (IV) version, Vyvgart Hytrulo is administered via injection under the skin, offering patients a more convenient and less time-consuming treatment option The main formulations of vyvgart hytrulo are intravenous (IV) and subcutaneous. Intravenous (IV) is a treatment administered directly into the bloodstream to target generalized myasthenia gravis, providing therapeutic benefits through a more controlled delivery method. It is used in indications such as generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The end users of this are adults and geriatrics and is distributed by channel, including hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Vyvgart Hytrulo Market Growth Forecast?

The growth in the forecast period can be attributed to increasing adoption of subcutaneous biologics, expansion into additional autoimmune indications, rising investments in neurology-focused therapies, growing preference for non-infusion treatments, continued innovation in antibody-based drugs. Major trends in the forecast period include increasing adoption of subcutaneous biologic formulations, rising demand for convenient autoimmune therapies, growing focus on fcrn inhibitor treatments, expansion of home and outpatient administration models, enhanced emphasis on patient convenience and compliance.

What Are The Drivers Of The Vyvgart Hytrulo Market?

The rising prevalence of autoimmune disorders is expected to propel the growth of the vyvgart hytrulo market going forward. Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own healthy cells and tissues, perceiving them as foreign or harmful. The rise in autoimmune diseases is largely attributed to a combination of genetic predisposition, environmental factors, infections, and changes in lifestyle, such as diet and increased exposure to chemicals. Vyvgart hytrulo is used in autoimmune diseases, specifically generalized myasthenia gravis (gMG), by reducing pathogenic antibodies through inhibition of the neonatal Fc receptor (FcRn). For instance, in August 2024, according to the Myasthenia Gravis Foundation of America, a US-based organization, myasthenia gravis affects approximately 150 to 200 individuals per million people worldwide. In the United States, it is estimated that 37 out of every 100,000 people have the condition. Therefore, the rising prevalence of autoimmune disorders is driving the vyvgart hytrulo industry. Increasing focus on personalized medicine is expected to boost the growth of the vyvgart hytrulo market going forward. Personalized medicine is an approach to medical treatment and healthcare that uses information about an individual's genetic makeup, lifestyle, and environment to tailor treatment plans specifically to that person for more effective outcomes. The increasing focus on personalized medicine is driven by advancements in genomics, technology, and data analytics, along with a growing demand for more precise, effective, and tailored treatment options. Vyvgart Hytrulo offers personalized medicine by targeting specific autoimmune mechanisms in patients with generalized myasthenia gravis (gMG), tailored to those who are positive for anti-AChR antibodies. For instance, in February 2024, according to the Personalized Medicine Coalition (PMC), a US-based nonprofit organization, the Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients in 2023, up from six in the previous year. Therefore, increasing focus on personalized medicine is driving the growth of the vyvgart hytrulo industry.

Key Players In The Global Vyvgart Hytrulo Market

Major companies operating in the vyvgart hytrulo market are Argenx SE

Global Vyvgart Hytrulo Market Trends and Insights

The key trend in the vyvgart hytrulo market is the advancement of targeted therapy, which offers a more flexible and effective treatment option for patients with generalized myasthenia gravis (gMG). Targeted therapy utilizes drugs or other substances designed to specifically target and interfere with the molecules involved in the growth and spread of diseases, thereby minimizing harm to healthy cells. For instance, in June 2023, argenx SE, a Netherlands-based immunology company, received U.S. FDA approval for VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for subcutaneous use in treating gMG. This approval marks a significant advancement in gMG treatment, providing patients with the flexibility of a subcutaneous injection option. VYVGART hytrulo has demonstrated efficacy comparable to its intravenous counterpart, showing a reduction in anti-AChR antibody levels while maintaining a favorable safety profile. This treatment offers patients a more convenient and personalized approach, allowing them to administer it in various settings, such as infusion centers or at home. As a result, it enhances overall patient convenience and promotes better treatment adherence.

What Defines the Vyvgart Hytrulo Market?

The vyvgart hytrulo market consists of sales of injections and solutions. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Vyvgart Hytrulo Market Report 2026?

The vyvgart hytrulo market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the vyvgart hytrulo industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.